Loading
Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.
Amod A. Sarnaik is a Surgical Oncologist in Cutaneous Oncology and a Senior Member at Moffitt Cancer Center, specialising in melanoma surgery and cellular immunotherapy. He is known as principal investigator of C-144-01, the pivotal trial of lifileucel that produced the first approved tumour-infiltrating lymphocyte therapy, with accelerated approval in advanced melanoma in 2024. His selected paper reports lifileucel, a tumour-infiltrating lymphocyte therapy, in metastatic melanoma. He continues to combine melanoma surgery with the development of TIL therapy at Moffitt.
| Title | Journal | Year |
|---|---|---|
| Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma | Journal of Clinical Oncology | 2021 |
| C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed | Journal of Clinical Oncology | 2021 |
Shares Lifileucel, TIL therapy, Melanoma.
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
Shares C-144-01, C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy.